Cytokeratin19-2g2, a Novel Fragment of Cytokeratin19 in Serum, Indicating a More Invasive Behavior and Worse Prognosis in Breast Cancer Patients

Abstract

BackgroundVarious studies have been searching for new tumor biomarkers for breast cancer for years. However, so far, few markers have been proved clinically useful except CA153. Based on knowledge that most adenocarcinomas including breast carcinoma expressed Cytokeratin19, the authors studied CK19-2G2,a novel fragment of cytokeratin19 shedding into serum in breast cancer patients.Patients and MethodsThe serum samples of four hundred and seventeen patients including three hundred and three (fifty-four DCIS and two hundred and forty-nine stage I-III) PBC patients and one hundred and fourteen MBC patients, eighty-one healthy controls and twenty-one breast benign disease patients were provided for measurement of CK19-2G2, CEA and CA153.The correlation between clinicopathological characters, prognosis and CK19-2G2 levels was further studied.ResultsThe serum CK19-2G2 levels in breast cancer patients were significantly higher than that in healthy and benign controls. For breast cancer patients, CK19-2G2 levels in MBC were significantly higher than that in PBC patients. The sensitivities of CK19-2G2 for breast carcinoma are as high as CEA and CA153, and up to 71% in MBC patients. Serum CK19-2G2 levels (≥2 mU/mL) were associated with pathological stages, tumor size (≥2 cm), lymph node involvement, and HER2 status. Multivariate analysis revealed that high serum CK19-2G2 level was an independent factor for relapse (P = 0.029) and death (P = 0.040) in breast cancer patients.ConclusionSerum CK19-2G2 may be an independent indicator for prognosis and a candidate marker for monitoring metastasis in breast cancer.

Keratins 17 and 19 expression as prognostic markers in oral squamous cell carcinoma

“…Other studies have shown the presence of K17 in gastric adenocarcinoma, Ewing sarcoma, OSCC, and ovary, breast, and cervical cancers (Maddox et al, 1999;Ide et al, 2012;Kitamura et al, 2012;Alshareeda et al, 2013;Sankar et al, 2013;Wang et al, 2013). K19 expression was shown in liver, breast, lung, ovary, thyroid and oral cancers (Safadi et al, 2010;Isic Dencic et al, 2013;Kong et al, 2013;Liu et al, 2013;Park et al, 2013). In a study with 56 OSCC samples and normal mucosal controls, 31 keratins were analyzed by high-density oligonucleotide microarrays (Toyoshima et al, 2008).…”

Clinical Pathological Analysis in 104 Ductal Breast Cancer Cases

“…There were statistically significant differences between different groups compassion. Recently, study confirmed, monitoring the prognosis marker on breast cancer metastasis has positive correlation with the tumor size [2]. For example, there is correction between high serum concentration (more than or equal to 2 mu/ml) ck19-2g2 and the tumor size (more than or equal to 2 cm).…”

Clinical pathological analysis in 104 ductal breast cancer cases

“…There were statistically significant differences between different groups compassion. Recently, study confirmed, monitoring the prognosis marker on breast cancer metastasis has positive correlation with the tumor size [2]. Such as, there is correction between high serum concentration (more than or equal to 2 mu / ml) ck19-2g2 and the tumor size (more than or equal to 2 cm).…”